Mats Jerkeman1, Christian Winther Eskelund2, Martin Hutchings2, Riikka Räty3, Karin Fahl Wader4, Anna Laurell5, Helle Toldbod6, Lone Bredo Pedersen2, Carsten Utoft Niemann2, Christina Dahl7, Hanne Kuitunen8, Christian H Geisler2, Kirsten Grønbæk2, Arne Kolstad9. 1. Department of Oncology, Institute of Clinical Sciences, Lund University and Skane University Hospital, Lund, Sweden. Electronic address: mats.jerkeman@med.lu.se. 2. Department of Haematology, Rigshospitalet, Copenhagen, Denmark; Biotech Research and Innovation Centre, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. 3. Department of Haematology, Helsinki University Hospital, Helsinki, Finland. 4. Department of Oncology, St Olav University Hospital, Trondheim, Norway. 5. Department of Oncology, Akademiska University Hospital, Uppsala, Sweden. 6. Clinical Trial Office, Department of Haematology, Aarhus University Hospital, Aarhus, Denmark. 7. Danish Cancer Society Research Center, Copenhagen, Denmark. 8. Department of Oncology, Oulu University Hospital, Oulu, Finland. 9. Department of Oncology, Oslo University Hospital, Oslo, Norway.
Abstract
BACKGROUND: Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published data on either regimen alone. METHODS: In this multicentre, open-label, single-arm, phase 2 trial, we enrolled patients aged 18 years or older with relapsed or refractory mantle cell lymphoma who had previously been treated with at least one rituximab-containing regimen, an Eastern Cooperative Oncology Group performance status score of 0-3, and at least one site of measurable disease, and who met criteria for several laboratory-assessed parameters. Treatment was divided into an induction phase of 12 cycles of 28 days with all three drugs and a maintenance phase with ibrutinib and rituximab only (cycle duration 56 days), given until disease progression or unacceptable toxicity. In the induction phase, patients received intravenous (375 mg/m2) or subcutaneous (1400 mg) rituximab once a week during cycle 1 and then once every 8 weeks. Oral ibrutinib (560 mg once a day) was given to patients every day in the cycle, whereas oral lenalidomide (15 mg once a day) was given on days 1-21. The primary endpoint was overall response assessed in the intention-to-treat population according to Lugano criteria. Safety analysis included all patients who received the treatment, irrespective of eligibility or duration of treatment. The trial is ongoing, but is no longer accruing patients, and is registered with ClinicalTrials.gov, number NCT02460276. FINDINGS:Between April 30, 2015, and June 1, 2016, we enrolled 50 patients with relapsed or refractory mantle cell lymphoma at ten centres in Sweden, Finland, Norway, and Denmark. At a median follow-up of 17·8 months (IQR 14·7-20·9), 38 (76%, 95% CI 63-86) patients had an overall response, including 28 (56%, 42-69) patients who had a complete response and ten (20%, 11-33) who had a partial response. The most common grade 3-4 adverse events were neutropenia (in 19 [38%] of 50 patients), infections (in 11 [22%] patients), and cutaneous toxicity (in seven [14%] patients). There were three treatment-related deaths during the study, two due to sepsis and one due to embolic stroke. INTERPRETATION: Our results provide preliminary evidence that the triplet combination of ibrutinib, lenalidomide, and rituximab is an active regimen in patients with relapsed or refractory mantle cell lymphoma, and should be evaluated in a prospective randomised controlled trial. FUNDING: Janssen and Celgene.
RCT Entities:
BACKGROUND: Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published data on either regimen alone. METHODS: In this multicentre, open-label, single-arm, phase 2 trial, we enrolled patients aged 18 years or older with relapsed or refractory mantle cell lymphoma who had previously been treated with at least one rituximab-containing regimen, an Eastern Cooperative Oncology Group performance status score of 0-3, and at least one site of measurable disease, and who met criteria for several laboratory-assessed parameters. Treatment was divided into an induction phase of 12 cycles of 28 days with all three drugs and a maintenance phase with ibrutinib and rituximab only (cycle duration 56 days), given until disease progression or unacceptable toxicity. In the induction phase, patients received intravenous (375 mg/m2) or subcutaneous (1400 mg) rituximab once a week during cycle 1 and then once every 8 weeks. Oral ibrutinib (560 mg once a day) was given to patients every day in the cycle, whereas oral lenalidomide (15 mg once a day) was given on days 1-21. The primary endpoint was overall response assessed in the intention-to-treat population according to Lugano criteria. Safety analysis included all patients who received the treatment, irrespective of eligibility or duration of treatment. The trial is ongoing, but is no longer accruing patients, and is registered with ClinicalTrials.gov, number NCT02460276. FINDINGS: Between April 30, 2015, and June 1, 2016, we enrolled 50 patients with relapsed or refractory mantle cell lymphoma at ten centres in Sweden, Finland, Norway, and Denmark. At a median follow-up of 17·8 months (IQR 14·7-20·9), 38 (76%, 95% CI 63-86) patients had an overall response, including 28 (56%, 42-69) patients who had a complete response and ten (20%, 11-33) who had a partial response. The most common grade 3-4 adverse events were neutropenia (in 19 [38%] of 50 patients), infections (in 11 [22%] patients), and cutaneous toxicity (in seven [14%] patients). There were three treatment-related deaths during the study, two due to sepsis and one due to embolic stroke. INTERPRETATION: Our results provide preliminary evidence that the triplet combination of ibrutinib, lenalidomide, and rituximab is an active regimen in patients with relapsed or refractory mantle cell lymphoma, and should be evaluated in a prospective randomised controlled trial. FUNDING: Janssen and Celgene.
Authors: Richard J Lin; Caleb Ho; Patrick D Hilden; Juliet N Barker; Sergio A Giralt; Paul A Hamlin; Ann A Jakubowski; Hugo R Castro-Malaspina; Kevin S Robinson; Esperanza B Papadopoulos; Miguel-Angel Perales; Craig S Sauter Journal: Br J Haematol Date: 2018-12-11 Impact factor: 6.998
Authors: Simon Rule; Martin Dreyling; Andre Goy; Georg Hess; Rebecca Auer; Brad Kahl; José-Ángel Hernández-Rivas; Keqin Qi; Sanjay Deshpande; Lori Parisi; Michael Wang Journal: Haematologica Date: 2018-11-15 Impact factor: 9.941
Authors: Peter Martin; Nancy L Bartlett; Kristie A Blum; Steven Park; Kami Maddocks; Jia Ruan; LeAnn Ridling; Christopher Dittus; Zhengming Chen; Xiangao Huang; Giorgio Inghirami; Maurizio DiLiberto; Selina Chen-Kiang; John P Leonard Journal: Blood Date: 2019-01-28 Impact factor: 22.113